🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization

Recruitingn/aAges 18 Years - 100 YearsAllSidney Kimmel Comprehensive Cancer Center at John…
NCT06389097 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The investigators will study SPECT imaging of radiopharmaceutical therapies given as standard of care or as part of other compatible research protocols. The goal is to validate the quantitative SPECT image reconstruction methods developed in this proposal, and to investigate the relation between dosimetry calculated from SPECT images and the outcomes. Patients will be recruited for SPECT/CT imaging during treatment. This is an observational study no additional new drugs or activities will be administrated. The investigators will perform SPECT imaging on a total of 80 patients (\~20 each from year 2 to year 5). Each participant will be imaged 3 times after the first and last cycles of planned radiopharmaceutical therapy.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Cohort A: Patients with advanced prostate cancer planning to undergo treatment with Radium-223 * Cohort B: Patients with advanced cancer undergoing treatment with 177Lu-DOTATATE or 177Lu-PSMA-617 \*\*Eligible patients may be planning to undergo these treatments as part of standard of care or as part of another research protocol * Age \> 18 years * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Histologic confirmation of malignancy Exclusion Criteria: * Patient is participating in another research protocol that does not allow participation in this imaging protocol or that has schedule of procedures that would not be compatible with this protocol. * Patient unable to tolerate SPECT scan time, scan frequency, or position.
💊

What it tests

  • Radium-223
  • 177Lu-DOTATATE
  • 177Lu-PSMA-617
📍

Where

1 site
Johns Hopkins University
Baltimore, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy